Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

The Roche deal was interesting for the reasons you say. I'd guess, though, that the royalty structure was reduced in that deal, so more up front but less going forward. HALO is learning how to play the game and so will probably structure these deals on a case by case basis depending on the prospects for future royalty streams.
-Fritz